A recent Swedish cohort study of primiparous women found that those who experienced gestational hypertension, preeclampsia, and eclampsia were at increased risk for new-onset neurological disorders months or years after giving birth.
A recent Swedish cohort study of primiparous women found that those who experienced gestational hypertension, preeclampsia, and eclampsia were at increased risk for new-onset neurological disorders months or years after giving birth.
A lifetime history of heavy cannabis use in young adults was associated with lower brain activation during a working memory task, according to a study in JAMA Network Open
A lifetime history of heavy cannabis use in young adults was associated with lower brain activation during a working memory task, according to a study in JAMA Network Open
The U.S. FDA is warning of rare, life-threatening allergic reactions associated with the injectable MS drug glatiramer acetate. Since its approval in 1996, 82 patients worldwide have required emergency care or hospitalization for anaphylaxis...
The U.S. FDA is warning of rare, life-threatening allergic reactions associated with the injectable MS drug glatiramer acetate. Since its approval in 1996, 82 patients worldwide have required emergency care or hospitalization for anaphylaxis...
Just over 3 years of intensive treatment to reduce systolic blood pressure in adults with hypertension and high cardiovascular risk resulted in a lower rate of cognitive impairment 7 years later, according to a study published in Neurology.
Just over 3 years of intensive treatment to reduce systolic blood pressure in adults with hypertension and high cardiovascular risk resulted in a lower rate of cognitive impairment 7 years later, according to a study published in Neurology.
Terumo Neuro Also Features Much-Anticipated SOFIA™ 88 Neurovascular Support Catheter Showcased at ISC Symposium led by Dr. Ameer E. Hassan on Thursday, February 6th
ALISO VIEJO, Calif. and LOS ANGELES, Feb. 5, 2025 /PRNewswire/ -- Terumo...
Terumo Neuro Also Features Much-Anticipated SOFIA™ 88 Neurovascular Support Catheter Showcased at ISC Symposium led by Dr. Ameer E. Hassan on Thursday, February 6th
ALISO VIEJO, Calif. and LOS ANGELES, Feb. 5, 2025 /PRNewswire/ -- Terumo...
The optimal times to assess sGFAP and sNfL when evaluating attacks in patients with neuromyelitis optica spectrum disorder (NMOSD) were within 1 week for sGFAP and 1 to 8 weeks for sNfL, according to study results published in JAMA Neurology.
The optimal times to assess sGFAP and sNfL when evaluating attacks in patients with neuromyelitis optica spectrum disorder (NMOSD) were within 1 week for sGFAP and 1 to 8 weeks for sNfL, according to study results published in JAMA Neurology.
The FDA has approved a supplemental biologics license application for lecanemab-irmb (Leqembi, Eisai Co., Ltd.; Biogen Inc.), an intravenous treatment (IV) for early Alzheimer disease (AD).
The FDA has approved a supplemental biologics license application for lecanemab-irmb (Leqembi, Eisai Co., Ltd.; Biogen Inc.), an intravenous treatment (IV) for early Alzheimer disease (AD).
Intra-arterial urokinase administered after near-complete or complete reperfusion by endovascular thrombectomy did not improve clinical outcomes in patients with acute ischemic stroke caused by large vessel occlusion, according to study...
Intra-arterial urokinase administered after near-complete or complete reperfusion by endovascular thrombectomy did not improve clinical outcomes in patients with acute ischemic stroke caused by large vessel occlusion, according to study...
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources
To view accreditation information/faculty disclosures for the program, click
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources
To view accreditation information/faculty disclosures for the program, click
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click...
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click...
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data
To view accreditation information/faculty disclosures for the program, click
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data
To view accreditation information/faculty disclosures for the program, click
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety DataTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation...
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety DataTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation...
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action
To view accreditation information/faculty disclosures for the program, click
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action
To view accreditation information/faculty disclosures for the program, click
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of ActionTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation button...
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of ActionTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation button...
Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease
To view accreditation information/faculty disclosures for the program, click
Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease
To view accreditation information/faculty disclosures for the program, click